Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments

29 Nov 2021

Abstract excerpt

Breast cancer (BC) is the most common cancer occurring in women but also rarely develops in men. Recent advances in early diagnosis and development of targeted therapies have greatly improved the survival rate of BC patients. However, the basal-like BC subtype (BLBC), largely overlapping with the triple-negative BC subtype (TNBC), lacks such drug targets and conventional cytotoxic chemotherapies often remain the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34845197
DOI: 10.1038/s41419-021-04407-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatmentsPMID 34845197Read ↗

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypesSemantic proximity Read ↗

Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted TherapiesSemantic proximity Read ↗

Recent Insights Into Breast Cancer: Molecular Pathways, Epigenetic Regulation, and Emerging Targeted TherapiesSemantic proximity Read ↗

HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer.Semantic proximity Read ↗

Deconstructing the molecular portrait of basal-like breast cancer.Semantic proximity Read ↗

Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectivesSemantic proximity Read ↗

Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug responseSemantic proximity Read ↗

Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional MachinerySemantic proximity Read ↗

Decoding gene regulatory circuitry underlying TNBC chemoresistance reveals biomarkers for therapy response and therapeutic targetsSemantic proximity Read ↗

Basal breast cancer: a complex and deadly molecular subtype.Semantic proximity Read ↗

BMI1 Polycomb Group Protein Acts as a Master Switch for Growth and Death of Tumor Cells: Regulates TCF4-Transcriptional Factor-Induced BCL2 SignalingSemantic proximity Read ↗

Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.